ArticleBritish journal of cancer2024
Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway.
Article in British journal of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Relationship between menopausal hormone therapy and incidence risk of breast cancer: systematic review and meta-analysis.Annals of medicine · 2026Pooled it
- Pooled it
- Trial
- Venom-Derived Peptides in Breast Cancer: Pharmacological Mechanisms and Medicinal Chemistry-Guided Translational Development.Archiv der Pharmazie · 2026Review
- Estrogen receptor-positive, BRCA1-deficient breast cancer: BRCA1-epimutated tumors presenting a piece to the puzzle.Breast cancer research : BCR · 2026Review
- Carcinogenic Medications: A Review of Specific Agents and Molecular Mechanisms of Carcinogenesis.Cancer reports (Hoboken, N.J.) · 2026Review
- Diet, the Gut Microbiome, and Estrogen Physiology: A Review in Menopausal Health and Interventions.Nutrients · 2026Review
- Reproductive Longevity: Innovative Approaches Beyond Hormone Replacement Therapy.Medicina (Kaunas, Lithuania) · 2026Review
- A Cross-Sectional Analysis of Women Attending a Free Screening Mammography Campaign at a University Hospital in Lebanon.International journal of women's health · 2026Article
- European Code Against Cancer, 5th edition - hormone replacement therapy, other common medical therapies and cancer.Molecular oncology · 2026Review
- Investigation of the mechanism of Yijing Decoction in the treatment of premature ovarian insufficiency: A network pharmacology study.Biochemistry and biophysics reports · 2025Article
- [Use of imaging methods in the current screening, diagnostics and treatment of breast cancer - Professional guidelines. 5th Breast Cancer Consensus Meeting (2025)].Magyar onkologia · 2025Article
- Association between daily sitting time and breast cancer among obese women: a nationwide population-based study.BMC women's health · 2025Article
- Exogenous Hormones, Tumor Intrinsic Subtypes, and Breast Cancer.JAMA network open · 2025Article
- Statins and the risk of gynecological cancer: a Norwegian population-based cohort study.International journal of epidemiology · 2025Article
- Comprehensive Analysis of Predictors and Outcomes in Breast Cancer Screening in Romania: Insights from Demographic, Clinical, and Lifestyle Factors.Journal of clinical medicine · 2025Article
- Synthesis, Anticancer Screening, and In Silico Evaluations of Thieno[2,3-Pharmaceuticals (Basel, Switzerland) · 2025Article
- Exploring the role of sex hormones and gender diversity in multiple sclerosis.Nature reviews. Neurology · 2025Article
- Menopausal hormone therapy and incidence, mortality, and survival of breast cancer subtypes: a prospective cohort study.Breast cancer research : BCR · 2024Article
- Review of non-antibiotic treatment and prevention of recurrent UTIs - a summary of current guidance and suggested treatment algorithm.Therapeutic advances in infectious diseaseArticle
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
Abstract
backgroundIt is important to monitor the association between menopausal hormone therapy (HT) use and breast cancer (BC) risk with contemporary estimates, and specifically focus on HT types and new drugs.
methodsWe estimated hazard ratios (HR) of BC risk according to HT type, administration route and individual drugs, overall and stratified by body mass index (BMI), molecular subtype and detection mode, with non-HT use as reference.
resultsWe included 1,275,783 women, 45+ years, followed from 2004, for a median of 12.7 years. Oral oestrogen combined with daily progestin was associated with the highest risk of BC (HR 2.42, 95% confidence interval (CI) 2.31-2.54), with drug-specific HRs ranging from Cliovelle®: 1.63 (95% CI 1.35-1.96) to Kliogest®: 2.67 (2.37-3.00). Vaginal oestradiol was not associated with BC risk. HT use was more strongly associated with luminal A cancer (HR 1.97, 95% CI 1.86-2.09) than other molecular subtypes, and more strongly with interval (HR 2.00, 95% CI: 1.83-2.30) than screen-detected (HR 1.33, 95% CI 1.26-1.41) BC in women 50-71 years. HRs for HT use decreased with increasing BMI.
conclusionsThe use of oral and transdermal HT was associated with an increased risk of BC. The associations varied according to HT type, individual drugs, molecular subtype, detection mode and BMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.